Salicylic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Salicylic Acid: From Topical Dermatological Use to Papillary Conjunctivitis
One-Sentence Summary
Salicylic acid is registered in South Africa only in topical products (a lotion and an ointment). The TxGNN model predicts it may be useful for papillary conjunctivitis, but there are currently no clinical trials and no publications supporting this direction. This is a model-only prediction that needs a literature review before any further work.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Papillary conjunctivitis |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this record. Salicylic acid is known to have anti-inflammatory activity through COX inhibition, and it acts as a keratolytic when applied to the skin. Papillary conjunctivitis is an inflammatory condition of the ocular surface (allergic or mechanical), so an anti-inflammatory link is plausible but indirect.
There is a major practical problem. Salicylic acid is an irritant and keratolytic, so applying the registered lotion or ointment to the eye would be unsafe. Any real use would need a completely different formulation and route, and route compatibility has not yet been assessed.
The other top predictions show that a high score alone is not reliable. Most of the other nine predictions are rare congenital skeletal or developmental disorders (for example pseudoachondroplasia, brachyolmia and brachydactyly-syndactyly syndrome), and none has a plausible mechanistic link. These scores are most likely knowledge-graph artifacts. The only other indirect candidates are rosacea conjunctivitis and spondyloarthropathy susceptibility, and both are also unsupported by evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. L13.4.1/66 | Diprosalic | Lotion |
| Reg. No. H/13.4.1/32 | Diprosalic | Ointment |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Ocular application of salicylic acid is a specific concern because of its irritant and keratolytic properties.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone, with no trials or publications. The only registered forms are topical skin products that are not suitable for ocular use.
To proceed, the following is needed:
- A literature review of salicylates and NSAIDs in allergic and papillary conjunctivitis
- Detailed mechanism of action data (MOA)
- The SAHPRA package insert, to obtain warnings and contraindications
- A route and formulation feasibility assessment, since no ocular formulation is registered
- The approved indication text for the registered products, which is currently blank in the registration data
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.